Response to Comments: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy

This policy (A59858) documents responses to comments on MolDX LCD DL39658 and does not itself define clinical coverage criteria. The LCD DL39658 will have a notice period starting 2024-08-08 and becomes effective 2024-09-22; consult DL39658 for specific indications, limitations, and documentation requirements for molecular biomarkers used to risk-stratify indeterminate pulmonary nodules after bronchoscopy.

"This document is a response to public comments on MolDX Local Coverage Determination DL39658 and does not itself state clinical coverage criteria; refer to DL39658 for molecular biomarker coverage ..."

Sign up to see full coverage criteria, indications, and limitations.